3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

Why It Matters

These high‑yield, dividend‑growth stocks deliver cash flow that can outpace rising consumer prices, offering investors a reliable income stream while preserving capital in a volatile macro environment.

Key Takeaways

• Amcor yields 6.3% with 27 years of dividend growth
• Chevron’s 3.6% yield backed by $20.2B free cash flow
• AbbVie offers 3.3% yield and 52‑year dividend streak
• All three span defensive sectors that outperform inflation

Pulse Analysis

Inflation remains stubbornly above the Federal Reserve’s 2% target, prompting investors to look beyond traditional fixed‑income solutions. High‑yield dividend stocks, especially those with a proven record of increasing payouts, act as a built‑in hedge because their cash distributions can rise faster than price levels. The three Dividend Aristocrats highlighted—Amcor, Chevron and AbbVie—each deliver yields exceeding 3%, positioning them as attractive income generators in an environment where bond yields are constrained and real returns are under pressure.

Amcor (AMCR) operates in the packaging sector, a defensive industry that benefits from consistent demand for food, beverage and pharmaceutical containers. Its 6.3% yield and 27‑year dividend streak come with a P/E of 27, suggesting a premium valuation but one justified by its market leadership and resilient cash flow. Chevron (CVX) leverages elevated oil prices to sustain a 3.6% yield, underpinned by $20.2 billion of free cash flow and a 38‑year dividend record, while also diversifying into LNG and renewables. AbbVie (ABBV) provides a 3.3% yield, a 52‑year payout streak, and record $61.2 billion revenue, driven by strong immunology sales, making health‑care exposure a stable counterbalance to inflation.

For portfolio construction, these stocks offer a blend of sector diversification and income stability. Investors should weigh valuation metrics—Amcor’s higher P/E, Chevron’s moderate price target upside, and AbbVie’s elevated P/E due to biotech growth—against the certainty of cash returns. While dividend cuts remain a risk in severe downturns, the aristocrat status signals strong balance sheets and disciplined capital allocation, making them suitable core holdings for income‑focused investors navigating an inflationary landscape.